Sotto Albert, Lefrant Jean Yves, Fabbro-Peray Pascale, Muller Laurent, Tafuri Jérôme, Navarro Francis, Prudhomme Michel, De La Coussaye Jean Emmanuel
Departments of Internal Medicine B, Critical Care and Emergency, Medical Biostatistics, Surgery A and Surgery B, University-Hospital of Nîmes, Nîmes, France.
J Antimicrob Chemother. 2002 Oct;50(4):569-76. doi: 10.1093/jac/dkf167.
To evaluate antimicrobial therapy management of secondary peritonitis in a University Hospital.
All patients admitted to the intensive care unit of the University Hospital of Nîmes from 1 January 1997 to 31 July 1999 with a diagnosis of secondary peritonitis were retrospectively included. Patients' medical records were collected from the data recordings of the Department of Critical Care and Emergency and the Departments of Surgery. Acute Physiology and Chronic Health Evaluation II (APACHE II) was calculated for each patient at the time of admission. Antimicrobial treatment management before and after the diagnosis of peritonitis was studied.
One hundred and twenty patients were included. Results concerning mortality, aetiology of peritonitis and microbiological data were in accordance with previous studies. APACHE II score (P = 0.005), age (P = 0.002), presence of Enterococcus in the peri-operative samples (P = 0.02) and period between diagnosis and surgery (P = 0.04) were predictive of death within 30 days after diagnosis of peritonitis. No significant difference was shown in the mortality rate in patients whose post-operative antibiotic treatment was changed following results of intra-operative peritoneal cultures versus patients having inappropriate treatment (P = 0.96). The same observations were noted for anti-enterococcal treatment.
This study emphasizes the importance of prompt surgical treatment and shows the modest impact of adapting antibiotic treatment. The morbidity and mortality associated with the presence of Enterococcus, which was not influenced by antibiotic treatment, would seem to suggest the pro-inflammatory role of Enterococcus. However, prospective randomized studies are needed to evaluate the real contribution of enterococcal antibiotic coverage in this context.
评估某大学医院继发性腹膜炎的抗菌治疗管理情况。
回顾性纳入1997年1月1日至1999年7月31日期间入住尼姆大学医院重症监护病房且诊断为继发性腹膜炎的所有患者。从重症监护与急诊科以及外科的数据记录中收集患者的病历。每位患者入院时计算急性生理与慢性健康状况评分系统II(APACHE II)。研究腹膜炎诊断前后的抗菌治疗管理情况。
共纳入120例患者。关于死亡率、腹膜炎病因及微生物学数据的结果与既往研究一致。APACHE II评分(P = 0.005)、年龄(P = 0.002)、围手术期样本中是否存在肠球菌(P = 0.02)以及诊断与手术之间的间隔时间(P = 0.04)可预测腹膜炎诊断后30天内的死亡情况。根据术中腹腔培养结果改变术后抗生素治疗的患者与接受不当治疗的患者相比,死亡率无显著差异(P = 0.96)。抗肠球菌治疗也有相同的观察结果。
本研究强调了及时手术治疗的重要性,并显示了调整抗生素治疗的适度影响。肠球菌的存在所导致的发病率和死亡率不受抗生素治疗影响,这似乎表明肠球菌具有促炎作用。然而,需要进行前瞻性随机研究来评估在这种情况下肠球菌抗生素覆盖的实际作用。